Should I buy or sell Cytek Biosciences stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTKB shares. View CTKB analyst ratings or view top-rated stocks .

What is Cytek Biosciences' stock price target for 2024?

5 brokerages have issued 1 year price targets for Cytek Biosciences' shares. Their CTKB share price targets range from $7.00 to $10.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 52.0% from the stock's current price. View analysts price targets for CTKB or view top-rated stocks among Wall Street analysts .

How have CTKB shares performed in 2024?

Cytek Biosciences' stock was trading at $9.12 on January 1st, 2024. Since then, CTKB shares have decreased by 35.1% and is now trading at $5.92. View the best growth stocks for 2024 here .

Are investors shorting Cytek Biosciences?

Cytek Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,950,000 shares, an increase of 16.9% from the March 15th total of 8,510,000 shares. Based on an average daily trading volume, of 723,300 shares, the days-to-cover ratio is currently 13.8 days. Currently, 8.4% of the company's stock are sold short. View Cytek Biosciences' Short Interest .

When is Cytek Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our CTKB earnings forecast .

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) posted its earnings results on Wednesday, August, 10th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.01. The firm earned $40.16 million during the quarter, compared to analysts' expectations of $41.34 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 1.40% and a negative net margin of 6.29%.

What ETF holds Cytek Biosciences' stock?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 446 shares of CTKB stock, representing 0.46% of its portfolio.

What guidance has Cytek Biosciences issued on next quarter's earnings?

Cytek Biosciences updated its FY 2024 earnings guidance on Thursday, April, 18th. The company provided EPS guidance of for the period. The company issued revenue guidance of $203.0 million-$213.0 million, compared to the consensus revenue estimate of $207.9 million.

When did Cytek Biosciences IPO?

Cytek Biosciences (CTKB) raised $248 million in an initial public offering on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CTKB

Cytek Biosciences (CTKB) Stock Price, News & Analysis

→ Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad)

Free CTKB Stock Alerts

$5.92

-0.05 (-0.84%)

(As of 04/17/2024 ET)

Compare

Today's Range: $5.91
▼
$6.12
50-Day Range: $5.92
▼
$9.15
52-Week Range: $3.80
▼
$12.31

Volume: 709,469 shs
Average Volume: 749,317 shs
Market Capitalization: $774.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Get Cytek Biosciences alerts:

Cytek Biosciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 52.0% Upside
$9.00 Price Target
Short Interest: Bearish
8.35% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.57
Based on 6 Articles This Week
Insider Trading: Selling Shares
$148,700 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.04) to $0.07 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.00 out of 5 stars

Medical Sector

564th out of 913 stocks

Analytical Instruments Industry

16th out of 26 stocks

3.3

Analyst's Opinion

Consensus Rating
Cytek Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cytek Biosciences has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.35% of the float of Cytek Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Cytek Biosciences has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Cytek Biosciences has recently increased by 16.92%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cytek Biosciences does not currently pay a dividend.
Dividend Growth
Cytek Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CTKB.

3.7

News and Social Media Coverage

News Sentiment
Cytek Biosciences has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Cytek Biosciences this week, compared to 2 articles on an average week.
Search Interest
5 people have searched for CTKB on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cytek Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $148,700.00 in company stock.
Percentage Held by Insiders
15.90% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cytek Biosciences are expected to grow in the coming year, from ($0.04) to $0.07 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cytek Biosciences is -65.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cytek Biosciences is -65.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cytek Biosciences has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Daily Market Alerts

Top 5 Tech Stocks to Buy for 2024

Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.

Click here to sign up for our free report & newsletter

About Cytek Biosciences Stock (NASDAQ:CTKB)

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CTKB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CTKB Stock News Headlines

April 13, 2024 | insidertrades.com

Ming Yan Sells 1,900 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock

March 20, 2024 | insidertrades.com

Cytek Biosciences, Inc. (NASDAQ:CTKB) CTO Ming Yan Sells 20,000 Shares

April 18, 2024 | Daily Market Alerts (Ad)

Top 5 Tech Stocks to Buy for 2024

Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.

April 12, 2024 | americanbankingnews.com

Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down to $6.91

March 27, 2024 | investorplace.com

CTKB Stock Earnings: Cytek Biosciences Beats Revenue for Q4 2023

March 21, 2024 | markets.businessinsider.com

Optimistic Outlook: Cytek Biosciences Poised for Growth with New CFO Appointment

March 20, 2024 | finance.yahoo.com

Insider Sell: Cytek Biosciences Inc's (CTKB) Chief Technology Officer Ming Yan Sells 40,000 Shares

March 19, 2024 | markets.businessinsider.com

Cytek Biosciences Names William McCombe To Succeed Patrik Jeanmonod As CFO; Reaffirms 2024 Outlook

April 18, 2024 | Daily Market Alerts (Ad)

Top 5 Tech Stocks to Buy for 2024

Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.

March 19, 2024 | globenewswire.com

Cytek® Biosciences Names William McCombe Chief Financial Officer

March 15, 2024 | finance.yahoo.com

CTKB Mar 2024 5.000 put

March 7, 2024 | globenewswire.com

Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions

March 7, 2024 | finanznachrichten.de

Cytek Biosciences, Inc.: Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

March 6, 2024 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)

March 1, 2024 | seekingalpha.com

Cytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call Transcript

March 1, 2024 | investing.com

Cytek Biosciences earnings matched, revenue topped estimates

March 1, 2024 | finance.yahoo.com

Cytek Biosciences Reports Full Year 2023 Earnings

March 1, 2024 | finance.yahoo.com

Cytek Biosciences Inc (CTKB) Reports Robust Revenue Growth and Positive Net Income in Q4 2023

February 29, 2024 | finance.yahoo.com

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2023 Earnings Call Transcript

February 28, 2024 | globenewswire.com

Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

February 13, 2024 | finance.yahoo.com

After losing 27% in the past year, Cytek Biosciences, Inc. (NASDAQ:CTKB) institutional owners must be relieved by the recent gain

January 17, 2024 | finance.yahoo.com

Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries

January 8, 2024 | finance.yahoo.com

Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results

December 28, 2023 | finance.yahoo.com

Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference

December 22, 2023 | finance.yahoo.com

Insider Sell: Cytek Biosciences Inc's CTO Ming Yan Disposes of 20,000 Shares

December 19, 2023 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Cytek Biosciences (CTKB)

December 14, 2023 | markets.businessinsider.com

Cytek's Full Spectrum Technology Stands Out In Cell Analysis Market, Bullish Analyst Says

See More Headlines

Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/10/2022
Today: 4/17/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:CTKB
CUSIP: N/A
CIK: 1831915
Web: www.cytekdev.com
Phone: 877-922-9835
Fax: N/A
Employees: 676
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.00
High Stock Price Target: $10.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +52.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,150,000.00
Net Margins: -6.29%
Pretax Margin: -8.14%
Return on Equity: -1.40%
Return on Assets: -1.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.97
Quick Ratio: 5.89

Sales & Book Value

Annual Sales: $193.01 million
Price / Sales: 4.01
Cash Flow: $0.02 per share
Price / Cash Flow: 238.67
Book Value: $2.90 per share
Price / Book: 2.04

Miscellaneous

Outstanding Shares: 130,820,000
Free Float: 110,023,000
Market Cap: $774.45 million
Optionable: Optionable
Beta: 1.37

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Wenbin Jiang Ph.D. (Age 60)
President, CEO & Chairman of the Board
Comp: $964.21k
Dr. Ming Yan Ph.D. (Age 61)
CTO & Director
Comp: $616.26k
Ms. Valerie T. Barnett J.D. (Age 48)
Chief Legal Officer
Comp: $535.98k
Mr. William D. McCombe (Age 66)
Chief Financial Officer
Mr. Chris Williams (Age 55)
Chief Operating Officer
Dr. Allen B. Poirson Ph.D. (Age 64)
Senior Vice President of Business & Corporate Development
Dr. Philippe Busque Ph.D.
Senior Vice President of Global Sales & Services
Mr. Patrik Sebastian Jeanmonod (Age 57)
Head of Corporate Development Analytics
Comp: $412.54k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CTKB Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytek Biosciences stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTKB shares.
View CTKB analyst ratings or view top-rated stocks.
What is Cytek Biosciences' stock price target for 2024?: 5 brokerages have issued 1 year price targets for Cytek Biosciences' shares. Their CTKB share price targets range from $7.00 to $10.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 52.0% from the stock's current price.
View analysts price targets for CTKB or view top-rated stocks among Wall Street analysts.
How have CTKB shares performed in 2024?: Cytek Biosciences' stock was trading at $9.12 on January 1st, 2024. Since then, CTKB shares have decreased by 35.1% and is now trading at $5.92.
View the best growth stocks for 2024 here.
Are investors shorting Cytek Biosciences?: Cytek Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,950,000 shares, an increase of 16.9% from the March 15th total of 8,510,000 shares. Based on an average daily trading volume, of 723,300 shares, the days-to-cover ratio is currently 13.8 days. Currently, 8.4% of the company's stock are sold short.
View Cytek Biosciences' Short Interest.
When is Cytek Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CTKB earnings forecast.
How were Cytek Biosciences' earnings last quarter?: Cytek Biosciences, Inc. (NASDAQ:CTKB) posted its earnings results on Wednesday, August, 10th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.01. The firm earned $40.16 million during the quarter, compared to analysts' expectations of $41.34 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 1.40% and a negative net margin of 6.29%.

What ETF holds Cytek Biosciences' stock?: First Trust Nasdaq Lux Digital Health Solutions ETF holds 446 shares of CTKB stock, representing 0.46% of its portfolio.
What guidance has Cytek Biosciences issued on next quarter's earnings?: Cytek Biosciences updated its FY 2024 earnings guidance on Thursday, April, 18th. The company provided EPS guidance of for the period. The company issued revenue guidance of $203.0 million-$213.0 million, compared to the consensus revenue estimate of $207.9 million.
When did Cytek Biosciences IPO?: Cytek Biosciences (CTKB) raised $248 million in an initial public offering on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share.
How do I buy shares of Cytek Biosciences?: Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTKB) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cytek Biosciences (CTKB) Stock Price, News & Analysis

Cytek Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cytek Biosciences Stock (NASDAQ:CTKB)

CTKB Stock Price History

CTKB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CTKB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™